LISATA THERAPEUTICS, INC. (LSTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 3.5M 7M 10.5M Q2 '16: 8.3M Q3 '16: 9.3M Q4 '16: 10.2M Q1 '17: 7.9M Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 1M Q1 '25: 0 Q2 '25: 70K Q3 '25: 0 Q4 '25: 100K Q1 '26: 0 Q2 '26: 0 Q3 '16 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 2.5M 5M 7.5M Q1 '10: 5M Q2 '10: 6.5M Q3 '10: 5.2M Q4 '10: 3.5M Q1 '11: 5.3M Q2 '11: 420.1K Q3 '11: 285.7K Q1 '12: 817K Q2 '12: 636.1K Q3 '12: 686.5K Q4 '12: 241.2K Q1 '13: 131.8K Q2 '13: 124.4K Q3 '13: 731K Q4 '13: 734K Q1 '10 Q3 '10 Q1 '11 Q3 '11 Q2 '12 Q4 '12 Q2 '13 Q4 '13

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -7M Q4 '21: -6.8M Q1 '22: -6.6M Q2 '22: -6.7M Q3 '22: -37.7M Q4 '22: -6.5M Q1 '23: -6.8M Q2 '23: -6.9M Q3 '23: -6M Q4 '23: -6M Q1 '24: -6.6M Q2 '24: -5.5M Q3 '24: -5.3M Q4 '24: -4.9M Q1 '25: -5.8M Q2 '25: -4.9M Q3 '25: -4.4M Q4 '25: -3.1M Q1 '26: -4.9M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -6.9M Q4 '21: -6.8M Q1 '22: -4.2M Q2 '22: -6.6M Q3 '22: -37.4M Q4 '22: -6M Q1 '23: -6.2M Q2 '23: -4M Q3 '23: -5.3M Q4 '23: -5.4M Q1 '24: -5.4M Q2 '24: -5M Q3 '24: -4.9M Q4 '24: -4.6M Q1 '25: -4.7M Q2 '25: -4.7M Q3 '25: -4.2M Q4 '25: -3M Q1 '26: -4.5M Q2 '26: -2.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q2 '12: 2.7M Q3 '12: 3.7M Q4 '12: 2.5M Q1 '13: 2.4M Q2 '13: 4.2M Q3 '13: 3M Q4 '13: 3.3M Q1 '14: 3.8M Q2 '14: 3.7M Q3 '14: 4M Q4 '14: 4.2M Q1 '15: 3.4M Q2 '15: 5.8M Q3 '15: 4.8M Q4 '15: 6.2M Q1 '16: 6.2M Q2 '16: 7.1M Q3 '16: 8.6M Q4 '16: 9.2M Q1 '17: 8M Q3 '12 Q2 '13 Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17

Operating Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '21: -5M Q4 '21: -4.6M Q1 '22: -5.6M Q2 '22: -5.1M Q3 '22: -4M Q4 '22: -6.5M Q1 '23: -8.2M Q2 '23: -4.2M Q3 '23: -3.6M Q4 '23: -4.1M Q1 '24: -7M Q2 '24: -5.3M Q3 '24: -2.5M Q4 '24: -4.5M Q1 '25: -5.4M Q2 '25: -4M Q3 '25: -3.3M Q4 '25: -3.2M Q1 '26: -3.1M Q2 '26: -2.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-9M -6M -3M 0 3M 6M 9M Q3 '20: -3.5M Q4 '20: -5.6M Q1 '21: -8M Q2 '21: -4.7M Q3 '21: -5M Q4 '21: -4.6M Q3 '22: -4M Q4 '22: -6.5M Q3 '23: -3.6M Q4 '23: -4.1M Q1 '24: -7M Q2 '24: -5.3M Q3 '24: -2.5M Q4 '24: -4.5M Q1 '25: -5.4M Q2 '25: -4M Q3 '25: -3.3M Q4 '25: -3.2M Q1 '26: -3.1M Q2 '26: -2.6M Q4 '20 Q3 '21 Q4 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 10.6M Q2 '20: 13.2M Q3 '20: 18.6M Q1 '21: 42.1M Q2 '21: 59.5M Q3 '21: 4M Q1 '22: 4M Q2 '22: 4M Q3 '22: 4.7M Q1 '23: 8M Q2 '23: 8M Q3 '23: 8.1M Q1 '24: 8.3M Q2 '24: 8.3M Q3 '24: 8.3M Q1 '25: 8.6M Q2 '25: 8.6M Q3 '25: 8.7M Q1 '26: 9M Q2 '26: 9.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -2.37 Q4 '21: -3.72 Q1 '22: -4.58 Q2 '22: -6.12 Q3 '22: -12.26 Q4 '22: -10.47 Q1 '23: -10.19 Q2 '23: -9.05 Q3 '23: -1.82 Q4 '23: -2.58 Q1 '24: -2.46 Q2 '24: -2.57 Q3 '24: -2.51 Q4 '24: -2.40 Q1 '25: -2.30 Q2 '25: -2.23 Q3 '25: -2.13 Q4 '25: -1.91 Q1 '26: -1.86 Q2 '26: -1.64 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.